Hormonal
Metformin produces a gene expression pattern closely aligned with long-term calorie restriction in mice, making it a promising calorie restriction mimetic candidate.
Metformin, a common diabetes drug, has been shown in mice to activate genes similar to those activated by calorie restriction. While this makes it a candidate for anti-aging benefits, the paper does not recommend it as a standalone longevity supplement for healthy humans without medical supervision, noting it is one of several candidates under investigation.
In an impressive study in mice evaluating the potential of several candidate CRM using microarray profiling, Dhahbi et al. (2005) reported that the 8 weeks’ treatment with metformin produced a gene expression pattern that was closely aligned with long-term CR.
Why this rating
Based on microarray profiling in mice showing gene alignment with CR, which is strong mechanistic evidence, though lifespan data is not the primary focus of this specific quote.
Source
Calorie restriction mimetics: an emerging research field
Donald K. Ingram et al. · Aging Cell · 2006
DOI 10.1111/j.1474-9726.2006.00202.x
More from this paper
- 2-deoxy-D-glucose (2DG) acts as a calorie restriction mimetic by inhibiting glycolysis, thereby reducing plasma insulin and body temperature without significantly reducing food intake or body weight in rats.Moderate
- Resveratrol, a sirtuin-activating compound (STAC), increases lifespan in nematodes and fruit flies in a Sir2-dependent manner, mimicking calorie restriction.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →